gadodiamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diagnostic agents, gadolinium derivatives	4494	131410-48-5

Description:

Molecule	Description
Synonyms: omniscan gadodiamide	for intravenous administration with MRI in adult patients for contrast enhancement of CNS lesions Molecular weight: 573.66 Formula: C16H26GdN5O8 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

omniscan
gadodiamide

for intravenous administration with MRI in adult patients for contrast enhancement of CNS lesions

Molecular weight: 573.66
Formula: C16H26GdN5O8
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	0.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.79 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.46 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 8, 1993	FDA	GE HEALTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	2174.70	52.95	346	2608	3976	50598194
Skin hypertrophy	402.61	52.95	79	2875	3016	50599154
Skin induration	401.28	52.95	78	2876	2833	50599337
Skin tightness	305.79	52.95	65	2889	3698	50598472
Fibrosis	195.26	52.95	45	2909	3702	50598468
Skin fibrosis	194.45	52.95	35	2919	824	50601346
Skin hyperpigmentation	150.37	52.95	39	2915	5237	50596933
Joint range of motion decreased	147.07	52.95	51	2903	18461	50583709
Joint contracture	108.14	52.95	24	2930	1660	50600510
Scar	103.32	52.95	35	2919	11783	50590387
Emotional distress	92.09	52.95	41	2913	28622	50573548
Skin discolouration	89.94	52.95	42	2912	32715	50569455
Anhedonia	78.51	52.95	27	2927	9497	50592673
Peau d'orange	75.03	52.95	12	2942	134	50602036
Joint stiffness	74.44	52.95	36	2918	30272	50571898
Mobility decreased	73.59	52.95	50	2904	79898	50522272
Oedema peripheral	69.73	52.95	64	2890	157897	50444273
Erythema	67.90	52.95	61	2893	146353	50455817
Skin plaque	64.29	52.95	21	2933	6307	50595863
Deformity	63.46	52.95	22	2932	7918	50594252
Pain	62.03	52.95	116	2838	578787	50023383
Muscle contracture	60.19	52.95	14	2940	1193	50600977
Extremity contracture	59.72	52.95	14	2940	1234	50600936
Magnetic resonance imaging head abnormal	54.81	52.95	14	2940	1763	50600407

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	2272.46	49.28	386	2768	3556	29567817
Skin hypertrophy	374.99	49.28	79	3075	2324	29569049
Skin tightness	355.38	49.28	73	3081	1891	29569482
Skin induration	352.12	49.28	73	3081	1981	29569392
Joint range of motion decreased	240.72	49.28	66	3088	5988	29565385
Joint contracture	234.30	49.28	51	3103	1749	29569624
Skin fibrosis	215.08	49.28	43	3111	964	29570409
Fibrosis	178.61	49.28	43	3111	2316	29569057
Scar	165.07	49.28	48	3106	5371	29566002
Extremity contracture	131.26	49.28	27	3127	699	29570674
Deformity	128.05	49.28	30	3124	1434	29569939
Emotional distress	124.27	49.28	49	3105	13846	29557527
Mobility decreased	122.08	49.28	58	3096	25722	29545651
Joint stiffness	112.10	49.28	41	3113	9432	29561941
Anhedonia	103.48	49.28	36	3118	7164	29564209
Pain	87.56	49.28	99	3055	171333	29400040
Oedema peripheral	84.27	49.28	77	3077	103480	29467893
Injury	81.47	49.28	40	3114	19006	29552367
Skin disorder	70.19	49.28	31	3123	11587	29559786
Skin discolouration	67.79	49.28	33	3121	15376	29555997
Musculoskeletal stiffness	65.82	49.28	44	3110	37414	29533959
Skin hyperpigmentation	64.00	49.28	20	3134	2844	29568529
Anxiety	53.37	49.28	55	3099	85310	29486063

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	3059.04	52.38	500	4191	5392	64488649
Skin hypertrophy	607.44	52.38	123	4568	4406	64489635
Skin induration	581.39	52.38	117	4574	4058	64489983
Skin tightness	520.84	52.38	110	4581	4851	64489190
Skin fibrosis	314.40	52.38	59	4632	1400	64492641
Joint range of motion decreased	294.89	52.38	92	4599	19251	64474790
Joint contracture	263.79	52.38	55	4636	2264	64491777
Fibrosis	240.12	52.38	58	4633	4670	64489371
Scar	192.70	52.38	61	4630	13337	64480704
Biopsy brain abnormal	172.38	52.38	21	4670	8	64494033
Skin hyperpigmentation	169.51	52.38	47	4644	6504	64487537
Joint stiffness	143.94	52.38	61	4630	30343	64463698
Oedema peripheral	135.40	52.38	116	4575	210201	64283840
Mobility decreased	130.87	52.38	80	4611	85760	64408281
Skin discolouration	128.93	52.38	59	4632	35196	64458845
Emotional distress	127.69	52.38	59	4632	35979	64458062
Deformity	121.71	52.38	36	4655	6261	64487780
Anhedonia	120.05	52.38	43	4648	13663	64480378
Extremity contracture	114.42	52.38	26	4665	1599	64492442
Peau d'orange	102.40	52.38	18	4673	291	64493750
Skin disorder	100.15	52.38	46	4645	27634	64466407
Pain	95.65	52.38	155	4536	553356	63940685
Erythema	84.89	52.38	85	4606	186985	64307056
Muscle contracture	82.15	52.38	21	4670	2124	64491917
Skin plaque	81.87	52.38	29	4662	8911	64485130
Injury	74.69	52.38	48	4643	55944	64438097
Musculoskeletal stiffness	73.10	52.38	65	4626	123141	64370900
Magnetic resonance imaging head abnormal	65.57	52.38	18	4673	2394	64491647
Pruritus	64.19	52.38	95	4596	312305	64181736
Muscle tightness	61.66	52.38	25	4666	11090	64482951
Skin exfoliation	61.14	52.38	39	4652	44846	64449195
Anxiety	58.90	52.38	73	4618	202576	64291465
Pain of skin	58.25	52.38	23	4668	9524	64484517
Muscular weakness	57.92	52.38	58	4633	127280	64366761
Magnetic resonance imaging abnormal	56.62	52.38	17	4674	3106	64490935
Gait disturbance	56.54	52.38	66	4625	172089	64321952
Dry skin	54.14	52.38	38	4653	51123	64442918

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V08CA03	VARIOUS CONTRAST MEDIA MAGNETIC RESONANCE IMAGING CONTRAST MEDIA Paramagnetic contrast media
MeSH PA	D003287	Contrast Media
MeSH PA	D064907	Diagnostic Uses of Chemicals
FDA MoA	N0000175862	Magnetic Resonance Contrast Activity
FDA EPC	N0000180184	Paramagnetic Contrast Agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Magnetic resonance imaging	indication	113091000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D04284	KEGG_DRUG
4020689	VUID
N0000148302	NUI
4020689	VANDF
CHEBI:31642	CHEBI
CHEMBL1200346	ChEMBL_ID
C064925	MESH_SUPPLEMENTAL_RECORD_UI
6636	INN_ID
DB00225	DRUGBANK_ID
84F6U3J2R6	UNII
60754	PUBCHEM_CID
41144	RXNORM
10205	MMSL
4771	MMSL
d04083	MMSL
004259	NDDF
354088005	SNOMEDCT_US
396067007	SNOMEDCT_US
C0082646	UMLSCUI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
OMNISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0407-0690	INJECTION	287 mg	INTRAVENOUS	NDA	28 sections
OMNISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0407-0690	INJECTION	287 mg	INTRAVENOUS	NDA	28 sections
OMNISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0407-0690	INJECTION	287 mg	INTRAVENOUS	NDA	28 sections
OMNISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0407-0691	INJECTION	287 mg	INTRAVENOUS	NDA	28 sections